Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer

Maintenance pemetrexed offers survival benefit with well-tolerated toxicities for advanced non-squamous non-small cell lung cancer (NSCLC). We present 3 consecutively enrolled patients with advanced non-squamous NSCLC, receiving stereotactic ablative radiotherapy (SABR) for oligoprogressive disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Shao-Lun, Hsu, Feng-Ming, Chen, Kuan-Yu, Ho, Chao-Chi, Yang, James Chih-Hsin, Cheng, Jason Chia-Hsien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5043363/
https://www.ncbi.nlm.nih.gov/pubmed/27721771
http://dx.doi.org/10.1159/000448804

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5043363/
https://www.ncbi.nlm.nih.gov/pubmed/27721771
http://dx.doi.org/10.1159/000448804

Ejemplares similares